Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current

News

Citigroup Downgrades Bioage Labs to Neutral, Lowers Price Target to $7

Author: Benzinga Newsdesk | December 09, 2024 08:39am
Citigroup analyst Samantha Semenkow downgrades Bioage Labs (NASDAQ:BIOA) from Buy to Neutral and lowers the price target from $45 to $7.

Posted In: BIOA

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist